title: Parvovirus b19 infection in fetal deaths.
abstract: BACKGROUND
  Parvovirus B19 infection during pregnancy can lead to nonimmune fetal hydrops, miscarriage, and intrauterine fetal death (IUFD). Some studies have suggested that parvovirus B19 infection may surprisingly often result in nonhydropic fetal death during the third trimester, in the absence of maternal serological evidence of acute infection. This study was conducted to investigate the prevalence of parvovirus B19 DNA among fetuses from miscarriages and IUFDs.
  
  
  METHODS
  We retrospectively studied 535 unborn fetuses, including 120 fetuses from miscarriages and 169 from IUFDs. The control fetuses were 246 fetuses from induced abortions. All fetuses were autopsied from July 1992 through December 1995 and from January 2003 through December 2005 in Helsinki, Finland. The period included a major epidemic of parvovirus B19 infection in 1993. Formalin-fixed, paraffin-embedded fetal tissues were studied with use of a highly sensitive and specific PCR that was capable of detecting all 3 parvovirus B19 genotypes and by histologic examination. In addition, maternal parvovirus B19 serological status was determined.
  
  
  RESULTS
  Parvovirus B19 DNA was detected in 5 fetuses with gestational ages of 14, 22, 23, 30, and 39 weeks; these included fetuses from 4 (2.4%) of the 169 IUFDs and 1 (0.8%) of the 120 miscarriages. During the epidemic year 1993, the prevalence of parvovirus B19 DNA-positive fetal deaths was 6 times the prevalence during nonepidemic years. All 5 mothers of the parvovirus B19 DNA-positive fetuses had serological signs of acute parvovirus B19 infection close to the time of fetal death. The only nonhydropic fetus was full-term.
  
  
  CONCLUSIONS
  Our findings indicate that the prevalence of parvovirus B19 infection among fetuses from IUFDs is low. In particular, our findings did not verify the claimed high prevalence of third-trimester nonhydropic IUFDs associated with parvovirus B19.
authors.affiliation: Centre of Expertise for Health and Work Ability, Finnish Institute of Occupational Health, Helsinki, Finland. anita.riipinen@ttl.fi
authors.forename: Anita
authors.initials: A
authors.lastname: Riipinen
authors.forename: Elina
authors.initials: E
authors.lastname: Väisänen
authors.forename: Mika
authors.initials: M
authors.lastname: Nuutila
authors.forename: Markku
authors.initials: M
authors.lastname: Sallmen
authors.forename: Riitta
authors.initials: R
authors.lastname: Karikoski
authors.forename: Marja-Liisa
authors.initials: ML
authors.lastname: Lindbohm
authors.forename: Klaus
authors.initials: K
authors.lastname: Hedman
authors.forename: Helena
authors.initials: H
authors.lastname: Taskinen
authors.forename: Maria
authors.initials: M
authors.lastname: Söderlund-Venermo
mesh_terms: D037881:Aborted Fetus / Q000473:pathology / Q000821:virology*; D000914:Antibodies, Viral / Q000097:blood; D004279:DNA, Viral / Q000302:isolation & purification; D005260:Female; D005313:Fetal Death / Q000209:etiology*; D005387:Finland; D006801:Humans; D015160:Hydrops Fetalis / Q000209:etiology; D008297:Male; D010322:Parvoviridae Infections / Q000150:complications*; D016732:Parvovirus B19, Human / Q000302:isolation & purification*; D016133:Polymerase Chain Reaction / Q000379:methods; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D012189:Retrospective Studies
chemical_list: D000914:Antibodies, Viral; D004279:DNA, Viral